Trial Profile
CLEVER: CLadribine tablets - EValuation of therapy satisfaction - CLEVER
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLEVER
- Sponsors Merck Serono
- 15 Oct 2021 Primary endpoint has been met. (The primary endpoint is overall treatment satisfaction with Cladribine tablets as assessed by the Global Satisfaction subscale score of the questionnaire TSQM-14 (Version 1.4) in week 24.),as per Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 01 May 2020 Results (n=67) presented at the 72nd Annual Meeting of the American Academy of Neurology